Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Big News in Early-Stage HR+ Breast Cancer
A major milestone was announced yesterday by Roche: the phase III lidERA trial shows that the oral SERD giredestrant significantly improves invasive disease-free survival (iDFS) vs standard endocrine therapy in ER+/HER2– early breast cancer — making it the first oral SERD to outperform traditional endocrine therapy in the adjuvant setting.
Why this matters
For 25+ years, tamoxifen and aromatase inhibitors have been the standard of care. In the metastatic disease, oral SERDs are already reshaping treatment—especially for ESR1-mutated tumors. Now we may finally see these therapies move meaningfully into early-stage breast cancer.
lidERA highlights (press release)
- >4,100 patients with stage I–III, moderate/high-risk ER+ disease
- Statistically significant & clinically meaningful iDFS benefit
- OS immature but trending positive
- Well tolerated with no unexpected safety signals
- Side effects generally mild (fatigue, nausea, arthralgia), and oral SERDs may be better tolerated than aromatase inhibitors
Full results to be presented soon — but this could represent a paradigm shift in adjuvant endocrine therapy?
And the next big question:
How will CDK4/6 inhibitors fit into this evolving landscape?
An exploratory lidERA substudy will evaluate giredestrant + abemaciclib, potentially redefining optimal adjuvant therapy for high-risk ER+ disease.
More post featuring Matthew Kurian on OncoDaily.